Aquestive Therapeutics (AQST) Q2 2026 earnings review
Anaphylm Hurdles Cleared, But Debt Restructuring Obscures Bottom Line
Aquestive successfully hit its most critical milestone: completing the human factors and pharmacokinetic studies required by the FDA's Complete Response Letter for Anaphylm. Resubmission remains on track for Q3 2026. Financially, the quarter was a mixed bag. Total revenue beat expectations, growing 38% YoY to $13.8M, driven surprisingly by the legacy Suboxone business. However, net loss widened dramatically to $22.9M (from $13.5M a year ago) due to an $11.7M one-time charge for extinguishing debt. Looking past this accounting noise, underlying operational cash burn is improving, with Adjusted EBITDA loss shrinking to $5.2M. The company remains highly dependent on FDA timelines, as its $75M in launch funding from RTW is strictly contingent on Anaphylm's approval.
🐂 Bull Case
The company successfully completed both the human factors and PK studies requested in the January FDA CRL. With zero chemistry or manufacturing deficiencies cited, the Q3 2026 resubmission pathway is clear.
Manufacture and supply revenue grew 24% YoY to $11.9M. Despite being a sunsetting product, Suboxone shipments increased, providing non-dilutive gross profit to offset clinical burn.
🐻 Bear Case
The company has $98.5M in cash, but commercializing Anaphylm will require massive capital. The $75M RTW funding and additional $20M from Oaktree are completely contingent on FDA approval, leaving zero room for regulatory delays.
While R&D costs fell, SG&A surged 11% YoY to $14.1M due to heavy legal fees ($2.1M) and severance costs ($1.4M), raising questions about overhead efficiency heading into an expensive commercialization phase.
⚖️ Verdict: ⚪
Neutral. Management executed perfectly on the Anaphylm clinical requirements, which is the primary value driver. However, high overhead costs and the binary nature of the upcoming FDA review keep the risk profile elevated.
Key Themes
Anaphylm Resubmission Hurdles Cleared
The single most important update from this quarter is the successful completion of the human factors validation and pharmacokinetic (PK) studies. Management noted 'significant improvement' across every deficiency cited in the January CRL regarding packaging design and instructions. The PK study met primary endpoints with zero self-administration errors. This definitively clears the path for the Q3 2026 NDA resubmission, turning the narrative from clinical risk back to regulatory execution.
AdrenaVerse Pivots to Atopic Dermatitis
Aquestive is strategically expanding its AdrenaVerse platform (AQST-108 prodrug) beyond alopecia and into Atopic Dermatitis (AD). This is a massive shift in Total Addressable Market (TAM), targeting a U.S. prevalence of ~27.5M patients. The technological innovation lies in the prodrug's ability to control absorption in the dermis layer—downregulating inflammatory mediators and stabilizing mast cells without the systemic risks of oral JAK inhibitors. If preclinical data holds up, this elevates the platform from a niche pipeline asset to a major value driver.
Insulated from Tariff Macro Shocks
Management explicitly addressed the growing macro concern regarding global trade. Because Aquestive is a U.S.-based manufacturer with U.S.-domiciled intellectual property, its supply chain remains 'largely unaffected by both implemented and proposed government tariffs.' This provides an operational moat against geopolitical friction that competitors relying on European or Asian CDMOs do not have.
Legacy Suboxone Volatility
Manufacture and supply revenue grew 24% YoY to $11.9M. Management attributed this directly to 'increases in Suboxone revenues.' This contradicts previous quarters' narrative where Suboxone was labeled a 'sunsetting product' in 'gradual decline.' While near-term cash is welcome, a reliance on a volatile, sunsetting legacy product to prop up the base business creates revenue risk if the decline sharply resumes before Anaphylm scales.
Elevated Overhead Costs Contradict 'Lean' Narrative
Management frequently cites disciplined cost management ahead of the Anaphylm launch, but the data tells a different story. SG&A increased 11% YoY to $14.1M. Digging into the lines, this was driven by $2.1M in legal fees and $1.4M in severance costs (including accelerated share-based comp). Restructuring overhead eats directly into the launch runway, contradicting the narrative of pure, focused pre-commercial execution.
International Expansion Running in Parallel
While U.S. resubmission dominates the headlines, Aquestive is quietly lining up a massive global footprint for Anaphylm. Canadian regulatory applications are set for Q4 2026, followed by the European Union in Q1 2027, and the UK later in 2027. Management previously confirmed existing clinical data is sufficient for these bodies, meaning ex-U.S. out-licensing deals could become a near-term catalyst for non-dilutive capital.
Other KPIs
Accelerating. Up significantly from 37.2 million doses in the second quarter of 2025. This 28% volume jump drove the strong beat in Manufacture and Supply revenue, confirming the operational throughput of the Indiana facility remains highly robust.
A one-time non-cash charge incurred to completely refinance the company's 13.5% notes. While it heavily distorted GAAP Net Income for the quarter, it reflects the previously announced Oaktree debt restructuring that ultimately pushed principal payments out for several years and fortified the pre-launch balance sheet.
Accelerating. Up 62% from $0.8 million in Q2 2025, primarily driven by royalty revenue from Zevra. This line item continues to provide a high-margin padding to the income statement, though it lacks the explosive scale of the previous quarter's one-time $5.4M milestone.
Guidance
Stable. Unchanged from prior guidance. At the midpoint ($48.0M), this implies an acceleration of roughly 7.8% YoY compared to FY25's $44.5M. Given that H1 2026 revenue is already at $28.2M, the company is on a comfortable glide path to exceed the midpoint, barring a severe collapse in Suboxone orders in H2.
Stable. Unchanged from prior guidance. H1 2026 Adjusted EBITDA loss sits at just $6.9M. To hit the guided $30M-$35M loss range, management expects a massive acceleration in cash burn ($23M-$28M) in the second half of the year. This reflects the intense, pre-commercial launch scaling expected once the Anaphylm NDA is formally resubmitted in Q3.
Key Questions
Suboxone Revenue Dynamics
Suboxone shipments drove an unexpected 24% increase in manufacturing revenue despite prior warnings of gradual decline. Is this a temporary stocking dynamic by the partner, or a stabilization of the legacy product's market share?
Severance and Legal Overhang
SG&A was inflated by $3.5M in combined legal and severance costs. Are these restructuring and litigation expenses fully resolved in Q2, or should we model for continued administrative bloat in H2?
Expedited Review Confidence
You plan to request an expedited review upon Anaphylm resubmission. Given the FDA's strict adherence to standard PDUFA timelines for resubmissions involving clinical PK data, what precedent gives you confidence a sub-6-month review is achievable?
AQST-108 Clinical Timeline
With the pivot to include Atopic Dermatitis for AQST-108, how does this alter the clinical timeline for the asset, and when should we expect the next human study dosing to commence?